NEGGRAM
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEGGRAM is an oral suspension small-molecule drug approved in 1973 by Sanofi. The generic name and specific mechanism of action are not publicly disclosed in available data. The drug's exact indication profile cannot be determined from current records.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30), signaling reduced commercial team investment and potential restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal a mature, stable product with minimal hiring momentum. Career growth on NEGGRAM is limited; roles focus on maintaining market share and managing transition to generic competition.
Brand ManagerField Sales
Worked on NEGGRAM at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.